Table 3. Multiple analysis: evaluation of prognostic factors for OS.
| HR | 95% CI | P-value | |
|---|---|---|---|
| Age | 1.011 | 0.998–1.025 | 0.0923 |
| Sex | 1.452 | 1.103–1.912 | 0.0078 |
| Tumour size | 1.659 | 1.266–2.174 | 0.0002 |
| Number of metastatic lymph nodes | 1.417 | 1.069–1.879 | 0.0155 |
| Histopathological grading | 1.232 | 0.920–1.650 | 0.1623 |
| Location of tumour | 0.7833 | ||
| Left colon and sigmoid | 1.121 | 0.812–1.548 | |
| Flexures and transverse colon | 1.065 | 0.715–1.585 | |
| Treatment with LEV | 1.460 | 1.110–1.920 | 0.0069 |
| Treatment with IFN | 0.975 | 0.744–1.278 | 0.8539 |
For the HR, the reference category for categorical covariates was female for sex, ⩽3 metastatic lymph nodes for number of metastatic lymph nodes, G1/G2 for histopathological grading, caecum and right colon for location of tumour, no LEV for treatment with LEV and no IFN for treatment with IFN. OS=overall survival; LEV=levamisole; IFN=interferon alfa.